DaVita Inc. (NYSE:DVA) Stock Has Average Price Target of $233.43

Shares of DaVita Inc. (NYSE:DVA) have received an average recommendation of “Moderate Buy” from the seven ratings firms that are covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $233.43.

DVA has been the subject of several recent analyst reports. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $265.00 target price on shares of DaVita in a research report on Wednesday, August 5th. Oppenheimer set a $220.00 price objective on DaVita in a report on Friday, August 7th. Truist Financial dropped their target price on shares of DaVita from $250.00 to $215.00 and set a “hold” rating for the company in a research report on Friday, August 7th. Barclays lifted their target price on DaVita from $218.00 to $224.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 5th. Finally, UBS Group boosted their price objective on shares of DaVita from $235.00 to $270.00 and gave the company a “buy” rating in a report on Friday, July 10th.

DaVita Stock Up 0.1%

DVA stock traded up $0.27 during trading on Tuesday, hitting $182.05. 31,048 shares of the company’s stock traded hands, compared to its average volume of 893,150. The stock has a fifty day moving average price of $181.31 and a two-hundred day moving average price of $189.98. DaVita has a 52 week low of $101.00 and a 52 week high of $247.49. The stock has a market capitalization of $11.61 billion, a price-to-earnings ratio of 14.88, a price-to-earnings-growth ratio of 0.46 and a beta of 0.80.

DaVita (NYSE:DVA) last posted its earnings results on Tuesday, August 4th. The company reported $4.02 EPS for the quarter, topping the consensus estimate of $3.88 by $0.14. The firm had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.50 billion. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. DaVita’s quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.95 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, equities research analysts expect that DaVita will post 14.57 EPS for the current fiscal year.

Hedge Funds Weigh In On DaVita

A number of institutional investors have recently added to or reduced their stakes in DVA. NorthCrest Asset Manangement LLC acquired a new stake in DaVita in the 3rd quarter worth about $209,000. Wedmont Private Capital raised its holdings in DaVita by 13.3% in the 3rd quarter. Wedmont Private Capital now owns 2,082 shares of the company’s stock valued at $369,000 after buying an additional 244 shares during the last quarter. Farther Finance Advisors LLC grew its position in shares of DaVita by 62.1% in the 3rd quarter. Farther Finance Advisors LLC now owns 2,362 shares of the company’s stock valued at $413,000 after buying an additional 905 shares during the last quarter. Westwind Capital acquired a new stake in shares of DaVita during the third quarter worth $1,251,000. Finally, CoreCap Advisors LLC grew its stake in DaVita by 161.7% during the third quarter. CoreCap Advisors LLC now owns 157 shares of the company’s stock worth $27,000 after purchasing an additional 97 shares during the period. 90.12% of the stock is currently owned by institutional investors and hedge funds.

DaVita Company Profile

DaVita Inc is a healthcare company focused on kidney care and renal disease management. Through its DaVita Kidney Care business, the company provides outpatient dialysis treatments for people with end-stage kidney disease, including hemodialysis and peritoneal dialysis, as well as home dialysis support.

The company also operates hospital-based dialysis programs and offers clinical, administrative and care-coordination services intended to support patients across the kidney-care journey.